Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Upstream Bio (UPB) Common Equity: 2023-2025

Historic Common Equity for Upstream Bio (UPB) over the last 2 years, with Sep 2025 value amounting to $378.6 million.

  • Upstream Bio's Common Equity rose 336.16% to $378.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $378.6 million, marking a year-over-year increase of 336.16%. This contributed to the annual value of $469.9 million for FY2024, which is 481.60% up from last year.
  • Per Upstream Bio's latest filing, its Common Equity stood at $378.6 million for Q3 2025, which was down 7.38% from $408.7 million recorded in Q2 2025.
  • Over the past 5 years, Upstream Bio's Common Equity peaked at $469.9 million during Q4 2024, and registered a low of -$160.3 million during Q3 2024.
  • For the 3-year period, Upstream Bio's Common Equity averaged around $114.1 million, with its median value being -$112.2 million (2023).
  • The largest annual percentage gain for Upstream Bio's Common Equity in the last 5 years was 481.60% (2024), contrasted with its biggest fall of 42.87% (2024).
  • Over the past 3 years, Upstream Bio's Common Equity (Quarterly) stood at -$123.1 million in 2023, then skyrocketed by 481.60% to $469.9 million in 2024, then surged by 336.16% to $378.6 million in 2025.
  • Its last three reported values are $378.6 million in Q3 2025, $408.7 million for Q2 2025, and $445.6 million during Q1 2025.